Patents by Inventor Richard Greff
Richard Greff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110014290Abstract: The present invention provides for a method and apparatus to provide hemostasis at a blood vessel puncture site, having a hemostasis material and a clot formation accelerator, wherein said clot formation accelerator is substantially dispersed throughout said hemostasis material.Type: ApplicationFiled: September 22, 2010Publication date: January 20, 2011Applicant: BOSTON SCIENTIFIC SCIMED, INC.Inventors: Eduardo Chi Sing, Mark Ashby, Tin Tran, Richard Greff
-
Publication number: 20080097606Abstract: A medical device and methods to relieve joint pain and adapted for knee joint repair, replacement and augmentation. The invention discloses joint lubricant, particularly hyaluronate compositions and methods for treatment of osteoarthritis.Type: ApplicationFiled: October 15, 2007Publication date: April 24, 2008Inventors: Andrew Cragg, Richard Greff, George Wallace, Robert Socci, Jr., Jonathan Kagan, Rodlofo Quijano, Hosheng Tu
-
Publication number: 20080045922Abstract: A liquid embolic delivery system is provided for trapping an injected liquid embolic composition to prevent the liquid embolic from solidifying or otherwise passing outside of an embolization area. The delivery system includes a catheter for delivery of a liquid embolic composition and a containment member positioned at a distal end of the catheter which is shaped to trap the liquid embolic composition delivered through the lumen of the catheter. The containment member is formed as a brush, nest, sponge, swab, flexible sack, or other shape into and around which the liquid embolic composition is injected. The liquid embolic composition is trapped or meshes with the containment member during solidification containing the liquid embolic and preventing the embolic composition from passing into the blood stream.Type: ApplicationFiled: October 24, 2007Publication date: February 21, 2008Inventors: Andrew Cragg, Blair Walker, John Perl, Michael Jones, George Greene, George Wallace, Richard Greff
-
Publication number: 20070219583Abstract: The present invention provides for a method and apparatus to provide hemostasis at a blood vessel puncture site, having a hemostasis material and a clot formation accelerator, wherein said clot formation accelerator is substantially dispersed throughout said hemostasis material.Type: ApplicationFiled: June 14, 2004Publication date: September 20, 2007Inventors: Eduardo Sing, Mark Ashby, Tin Tran, Richard Greff
-
Publication number: 20050196341Abstract: Disclosed are methods for treating urinary incontinence in a mammal wherein a composition comprising a biocompatible polymer, a biocompatible solvent, and a contrast agent is delivered to the periurethral tissue of the mammal.Type: ApplicationFiled: March 29, 2005Publication date: September 8, 2005Applicant: Micro Therapeutics, Inc.Inventors: George Wallace, Richard Greff
-
Publication number: 20050169845Abstract: Disclosed are methods for treating urinary incontinence in a mammal wherein a composition comprising a biocompatible polymer, a biocompatible solvent, and a contrast agent is delivered to the periurethral tissue of the mammal.Type: ApplicationFiled: March 28, 2005Publication date: August 4, 2005Applicant: Micro Therapeutics, Inc.Inventors: George Wallace, Richard Greff
-
Publication number: 20050090714Abstract: This invention is directed to novel methods for gynecologic embolotherapy. The methods directly access the blood vessels to be embolized transcervically rather than arterially. The methods provide precise directed delivery of embolizing compositions, and are particularly suited for treating uterine fibroids. Kits containing one or more devices for transcervical injection and an embolizing composition are also provided. In a preferred embodiment, fluid embolizing compositions are used. In a more preferred embodiment, these fluid embolic compositions comprise a biocompatible polymer, a biocompatible solvent and a biocompatible water insoluble contrast agent. In a most preferred embodiment, the contrast agent is characterized by having an average particle size of about 10 ?m or less.Type: ApplicationFiled: May 13, 2004Publication date: April 28, 2005Inventor: Richard Greff
-
Publication number: 20050025707Abstract: This invention is directed to compositions for embolizing vascular sites. The compositions described herein comprise fumed silica as a rheological modifier. The fumed silica imparts high viscosity to the compositions under static conditions but allows the compositions to flow readily under shear conditions. This invention is also directed to methods for treatment of aneurysms, arteriovenous fistulae, arteriovenous malformations, tumors, and other vascular diseases using the compositions described herein. Other uses are disclosed as well. Kits of parts including those compositions and devices which can deliver these composition are also described.Type: ApplicationFiled: February 26, 2004Publication date: February 3, 2005Inventors: William Patterson, Richard Greff, Meyer Rosen, Earl Slee, Thomas Whalen
-
Patent number: 6335384Abstract: Disclosed are methods useful for treating vascular lesions wherein a non-particulate agent such as a metal coil is introduced into a vascular site (e.g., an aneurysm cavity) in conjunction with an embolizing composition comprising a biocompatible polymer and a biocompatible solvent. The biocompatible solvent is miscible or soluble in blood and also solubilizes the polymer during delivery. The biocompatible polymer is selected to be soluble in the biocompatible solvent but insoluble in blood. Upon contact with the blood, the biocompatible solvent dissipates from the embolic composition whereupon the biocompatible polymer precipitates. Precipitation of the polymer in the presence of the non-particular agent permits the agent to act as a structural lattice for the growing polymer precipitate. In another embodiment, the biocompatible polymer composition can be replaced with a biocompatible prepolymer composition containing a biocompatible prepolymer.Type: GrantFiled: October 10, 2000Date of Patent: January 1, 2002Assignee: Micro Therapeutics, Inc.Inventors: Scott Evans, John Perl, II, Richard Greff
-
Patent number: 6281263Abstract: Disclosed are methods useful for treating vascular lesions wherein a non-particulate agent such as a metal coil is introduced into a vascular site (e.g., an aneurysm cavity) in conjunction with an embolizing composition comprising a biocompatible polymer and a biocompatible solvent. The biocompatible solvent is miscible or soluble in blood and also solubilizes the polymer during delivery. The biocompatible polymer is selected to be soluble in the biocompatible solvent but insoluble in blood. Upon contact with the blood, the biocompatible solvent dissipates from the embolic composition whereupon the biocompatible polymer precipitates. Precipitation of the polymer in the presence of the non-particulate agent permits the agent to act as a structural lattice for the growing polymer precipitate. In another embodiment, the biocompatible polymer composition can be replaced with a biocompatible prepolymer composition containing a biocompatible prepolymer.Type: GrantFiled: November 12, 1999Date of Patent: August 28, 2001Inventors: Scott Evans, John Perl, II, Richard Greff
-
Patent number: 6017977Abstract: Disclosed are methods useful for treating vascular lesions wherein a non-particulate agent such as a metal coil is introduced into a vascular site (e.g., an aneurysm cavity) in conjunction with an embolizing composition comprising a biocompatible polymer and a biocompatible solvent.The biocompatible solvent is miscible or soluble in blood and also solubilizes the polymer during delivery. The biocompatible polymer is selected to be soluble in the biocompatible solvent but insoluble in blood. Upon contact with the blood, the biocompatible solvent dissipates from the embolic composition whereupon the biocompatible polymer precipitates. Precipitation of the polymer in the presence of the non-particulate agent permits the agent to act as a structural lattice for the growing polymer precipitate.In another embodiment, the biocompatible polymer composition can be replaced with a biocompatible prepolymer composition containing a biocompatible prepolymer.Type: GrantFiled: June 4, 1997Date of Patent: January 25, 2000Assignee: Micro Therapeutics, Inc.Inventors: Scott Evans, John Perl, II, Richard Greff
-
Patent number: 5702361Abstract: Disclosed are methods useful for treating vascular lesions wherein a non-particulate agent such as a metal coil is introduced into a vascular site (e.g., an aneurysm cavity) in conjunction with an embolizing composition comprising a biocompatible polymer and a biocompatible solvent.The biocompatible solvent is miscible or soluble in blood and also solubilizes the polymer during delivery. The biocompatible polymer is selected to be soluble in the biocompatible solvent but insoluble in blood. Upon contact with the blood, the biocompatible solvent dissipates from the embolic composition whereupon the biocompatible polymer precipitates. Precipitation of the polymer in the presence of the non-particulate agent permits the agent to act as a structural lattice for the growing polymer precipitate.In another embodiment, the biocompatible polymer composition can be replaced with a biocompatible prepolymer composition containing a biocompatible prepolymer.Type: GrantFiled: January 31, 1996Date of Patent: December 30, 1997Assignee: Micro Therapeutics, Inc.Inventors: Scott Evans, John Perl, II, Richard Greff
-
Patent number: 5695480Abstract: Disclosed are novel compositions for embolizing blood vessels which are particularly suited for treating vascular lesions via catheter delivery. In one embodiment, the compositions of this invention comprise a biocompatible polymer, a biocompatible solvent and a biocompatible water insoluble contrast agent characterized by having an average particle size of less than about 10 .mu.m.In another embodiment, the biocompatible polymer in these compositions is replaced with a biocompatible prepolymer.Type: GrantFiled: July 29, 1996Date of Patent: December 9, 1997Assignee: Micro Therapeutics, Inc.Inventors: Scott Evans, Michael L. Jones, Richard Greff
-
Patent number: 4242310Abstract: A sterile connection apparatus is provided for enabling the connection of a first tube to a transfer tube of a medical solution container. The apparatus includes a housing having a cover portion which is adapted for interfitting with a base portion to provide a substantially closed interior volume. The first tube and the transfer tube of the medical solution container are introduced within the interior volume and the housing carries means located therewithin and operable from the outside of the housing for enabling manipulation of one of the tubes. In this manner, the first tube may be disconnected from and/or connected to the transfer tube. Means are provided for sterilizing the tubes within the substantially closed interior volume.Type: GrantFiled: November 13, 1978Date of Patent: December 30, 1980Assignee: Baxter Travenol Laboratories, Inc.Inventors: Richard Greff, Ludwig Wolf, Jr., John Munsch, Layton C. Kinney